BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26272233)

  • 1. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.
    Freidin MB; Freydina DV; Leung M; Montero Fernandez A; Nicholson AG; Lim E
    Clin Chem; 2015 Oct; 61(10):1299-304. PubMed ID: 26272233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
    Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
    Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases.
    Wu J; Zhou Y; Zhang CY; Song BB; Wang BL; Pan BS; Lou WH; Guo W
    Asian Pac J Cancer Prev; 2014; 15(24):10647-52. PubMed ID: 25605154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
    Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
    J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
    Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
    Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosing peripheral lung cancer: the additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy.
    van der Drift MA; Prinsen CFM; Knuiman GJ; Janssen JP; Dekhuijzen PNR; Thunnissen FBJM
    Chest; 2012 Jan; 141(1):169-175. PubMed ID: 21700687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.
    Adams JA; Post KM; Bilbo SA; Wang X; Sen JD; Cornwell AJ; Malek AJ; Cheng L
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):231-5. PubMed ID: 24614151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products.
    Kristensen LS; Daugaard IL; Christensen M; Hamilton-Dutoit S; Hager H; Hansen LL
    Hum Mutat; 2010 Dec; 31(12):1366-73. PubMed ID: 20848649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
    Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
    Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
    Gautschi O; Huegli B; Ziegler A; Gugger M; Heighway J; Ratschiller D; Mack PC; Gumerlock PH; Kung HJ; Stahel RA; Gandara DR; Betticher DC
    Cancer Lett; 2007 Sep; 254(2):265-73. PubMed ID: 17449174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
    Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
    Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.